Detalles de la búsqueda
1.
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
J Thromb Thrombolysis
; 54(3): 461-469, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048358
2.
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
J Thromb Thrombolysis
; 54(3): 373-381, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36036856
3.
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.
J Thromb Thrombolysis
; 51(3): 741-747, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33582955
4.
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation
; 139(14): 1661-1670, 2019 04 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30630341
5.
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation
; 137(23): 2450-2462, 2018 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29526833
6.
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
J Transl Med
; 16(1): 92, 2018 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29642909
7.
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation
; 134(11): 780-92, 2016 Sep 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27559041
8.
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation
; 142(15): 1500-1502, 2020 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33044856
9.
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Thromb Haemost
; 124(3): 263-273, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37224883
10.
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
JACC Cardiovasc Interv
; 17(11): 1356-1370, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38597172
11.
Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic expression of TCF7L2.
BMC Genet
; 14: 28, 2013 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23617586
12.
Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
EuroIntervention
; 18(15): 1254-1265, 2023 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36602868
13.
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
JACC Cardiovasc Interv
; 16(1): 36-46, 2023 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36317958
14.
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
JACC Cardiovasc Interv
; 16(20): 2528-2539, 2023 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37609698
15.
Genetic variation in cholesterol ester transfer protein, serum CETP activity, and coronary artery disease risk in Asian Indian diabetic cohort.
Pharmacogenet Genomics
; 22(2): 95-104, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22143414
16.
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thromb Haemost
; 122(8): 1341-1351, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34983074
17.
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
Eur Heart J Cardiovasc Pharmacother
; 8(7): 728-737, 2022 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35353154
18.
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
Eur Heart J Cardiovasc Pharmacother
; 8(5): 452-461, 2022 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34114623
19.
Variants in KCNQ1 increase type II diabetes susceptibility in South Asians: a study of 3,310 subjects from India and the US.
BMC Med Genet
; 12: 18, 2011 Jan 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21261977
20.
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ Open Diabetes Res Care
; 9(1)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33637605